Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract

TED-PAEDIATRIC — structured trial abstract

TED-PAEDIATRIC — Teduglutide in mucosal barrier: single-arm open-label

Document identifier
CEI-TR-0154
Series
Trial abstract
Version
3.2
Published
13 Feb 2023
Last reviewed
13 Dec 2023
Next review
13 Dec 2025
Identifier
10.71829/cei.trial.154
Certainty
Moderate
Cycle
2023 Q1
Phase
Phase 3
Status
Reported

§1Structured abstract

§1.1Objective

To evaluate Teduglutide in inflammatory bowel disease and mucosal barrier disorders, against the comparator specified in §2, with the primary endpoint stated below.

§1.2Design

Design
Single-arm open-label study
Masking
None
Phase
Phase 3
Randomised participants
59
Duration of the primary analysis period
24 weeks
Sponsor class
Manufacturer-sponsored
Registry identifier
not reproduced — see the note in §1.5

§1.3Primary endpoint

Reduction in parenteral support volume in paediatric short-bowel syndrome

§1.4Principal result

A reduction in parenteral support requirement. The Institute records that the compound has an approved indication distinct from the uses under which analogues are supplied for research.

§1.5Provenance of this abstract

Table 1. Field-by-field provenance. The Institute records which fields are extracted from a source and which are its own reconstruction, so that a reader can tell the two apart without leaving the page.

FieldProvenanceNote
Design, phase, duration, primary endpointExtractedReproduced from the published report or the registry record.
Randomised participantsExtractedReproduced as published.
Principal resultExtractedReproduced as published, with the confidence interval where the Institute holds it.
Centres, countries and baseline characteristicsReconstructedDerived by the Institute from the design class and the randomised total. Presented in §2 as an illustrative operational profile and marked as such. These figures are not published characteristics of this trial.
Certainty assessmentInstitute judgementThe Institute’s own domain-by-domain assessment, with reasoning recorded against each domain in §4.
Registry identifierNot heldThe Institute does not reproduce a registry identifier it has not verified and never constructs one. Documents are referenced by the Institute’s own identifier.
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.